Phase 2 Pancreatic Ductal Adenocarcinoma trials recruiting now

All Pancreatic Ductal Adenocarcinoma trials, every phase

Other phases for Pancreatic Ductal Adenocarcinoma

Phase 2 Pancreatic Ductal Adenocarcinoma trials

• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
  NCT06503146 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  NCT06428409 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
  NCT06079346 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
  NCT06598007 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
  NCT06219941 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
  NCT06831136 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
  NCT07483554 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lead-212 PSV359 Therapy for Patients With Solid Tumors
  NCT06710756 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 22 locations
• Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
  NCT07199764 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
  NCT06782412 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
  NCT04146298 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
  NCT05132504 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Reinforced Pancreaticojejunostomy With or Without glubran2
  NCT06756074 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
  NCT05482893 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
  NCT06005493 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  NCT05254171 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
  NCT05257993 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 79 Years · Sex: All (male and female) · 4 locations
• Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
  NCT07219238 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
  NCT07284277 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · 42 locations
• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
  NCT07432633 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
  NCT03608631 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.